A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control

Nutrition Journal

Volumn 10, Issue 1, 2011, Pages

  Barrett, Marilyn L ^a   Udani, Jay K ^b,c  

^a Pharmacognosy Consulting   (United States)

^b Medicus Research LLC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; AMYLASE INHIBITOR; ANTIOBESITY AGENT; CARB INTERCEPT; CHROMIUM PICOLINATE; GLUCOSE; NATROL; PHASE 2; PHASEOLAMIN; PHASEOLUS VULGARIS EXTRACT; PLACEBO; PLANT EXTRACT; PRECARB; STARCHAWAY; SUCO BLOC; THERA SLIM; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

AREA UNDER THE CURVE; BLOATING; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; ENZYME INHIBITION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; NONHUMAN; OBESITY; PHASEOLUS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; WEIGHT REDUCTION; ADULT; BEAN; CHEMISTRY; CHILD; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

PHASEOLUS VULGARIS;

ADULT; ALPHA-AMYLASES; BLOOD GLUCOSE; CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLYCEMIC INDEX; HUMANS; OBESITY; PHASEOLUS; PLANT EXTRACTS; WEIGHT LOSS;

EID: 79952702622     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-10-24     Document Type: Review

References (50)

1. Obesity and overweight. World Health Organization, 2006 http://www.who.int/mediacentre/factsheets/fs311/en/index.html Ref Type: Online Source
2. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. HG Preuss, J Am Coll Nutr 2009 28 266 276 20150600
3. The nutraceutical role of the Phaseolus vulgaris alpha-amylase inhibitor. WC Obiro T Zhang B Jiang, Br J Nutr 2008 100 1 12 10.1017/S0007114508879135 18331662
4. Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Report. Food and Agriculture Organization, World Health Organization, FAO Food and Nutrition paper 1998 66 1 140 9743703
5. Metabolic effects of low glycaemic index diets. G Radulian E Rusu A Dragomir M Posea, Nutr J 2009 8 5 10.1186/1475-2891-8-5 19178721
6. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. S Yamagishi T Matsui S Ueda K Fukami S Okuda, Curr Drug Metab 2009 10 159 163 10.2174/138920009787522133 19275550
7. Dietary glycemic index: health implications. J Brand-Miller J McMillan-Price K Steinbeck I Caterson, J Am Coll Nutr 2009 28 446S 449S 20234031
8. Glycemic index, glycemic load, and chronic disease risk - a meta-analysis of observational studies. AW Barclay P Petocz J McMillan-Price VM Flood T Prvan P Mitchell,, et al. Am J Clin Nutr 2008 87 627 637 18326601 (Pubitemid 351364544)
9. Low glycaemic index or low glycaemic load diets for overweight and obesity. DE Thomas EJ Elliott L Baur, Cochrane Database Syst Rev 2007 D005105 17636786
10. Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. S Krishnan L Rosenberg M Singer FB Hu L Djousse LA Cupples,, et al. Arch Intern Med 2007 167 2304 2309 10.1001/archinte.167.21.2304 18039988 (Pubitemid 350179524)
11. Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. R Villegas S Liu YT Gao G Yang H Li W Zheng,, et al. Arch Intern Med 2007 167 2310 2316 10.1001/archinte.167.21.2310 18039989 (Pubitemid 350179525)
12. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. MB Schulze S Liu EB Rimm JE Manson WC Willett FB Hu, Am J Clin Nutr 2004 80 348 356 15277155 (Pubitemid 41080008)
13. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. MB Schulze M Schulz C Heidemann A Schienkiewitz K Hoffmann H Boeing, Arch Intern Med 2007 167 956 965 10.1001/archinte.167.9.956 17502538 (Pubitemid 46762759)
14. Carbohydrate bioavailability. KN Englyst HN Englyst, Br J Nutr 2005 94 1 11 10.1079/BJN20051457 16115326 (Pubitemid 41357803)
15. Low-digestible carbohydrates in practice. HA Grabitske JL Slavin, J Am Diet Assoc 2008 108 1677 1681 10.1016/j.jada.2008.07.010 18926133
16. Resistant starch: metabolic effects and potential health benefits. JA Higgins, J AOAC Int 2004 87 761 768 15287677
17. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. R Tundis MR Loizzo F Menichini, Mini Rev Med Chem 2010 10 315 331 10.2174/ 138955710791331007 20470247
18. The inhibitory effects of berry polyphenols on digestive enzymes. GJ McDougall D Stewart, Biofactors 2005 23 189 195 10.1002/biof.5520230403 16498205 (Pubitemid 43264769)
19. Evaluation of different teas against starch digestibility by mammalian glycosidases. LW Koh LL Wong YY Loo S Kasapis D Huang, J Agric Food Chem 2010 58 148 154 10.1021/jf903011g 20050703
20. Characterization of alpha-Amylase-Inhibitor, a Lectin-Like Protein in the Seeds of Phaseolus vulgaris. J Moreno T Altabella MJ Chrispeels, Plant Physiol 1990 92 703 709 10.1104/pp.92.3.703 16667338 (Pubitemid 120029745)
21. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. P Layer GL Carlson EP DiMagno, Gastroenterology 1985 88 1895 1902 2581844 (Pubitemid 15052303)
22. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. P Layer AR Zinsmeister EP DiMagno, Gastroenterology 1986 91 41 48 2423408 (Pubitemid 16086652)
23. Quality control study of H2 breath testing for the diagnosis of carbohydrate malabsorption in Italy. The "Tenue Club" Group. A Strocchi GR Corazza C Anania G Benati S Malservisi MV Cherchi,, et al. Ital J Gastroenterol Hepatol 1997 29 122 127 9646191
24. Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria. A Strocchi G Corazza CJ Ellis G Gasbarrini MD Levitt, Gastroenterology 1993 105 1404 1410 8224644 (Pubitemid 23315315)
25. Lactose malabsorption. Optimalization of investigational methods. RJ Brummer M Karibe RW Stockbrugger, Scand J Gastroenterol Suppl 1993 200 65 69 10.3109/00365529309101578 8016574 (Pubitemid 24093227)
26. Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus. P Layer RA Rizza AR Zinsmeister GL Carlson EP DiMagno, Mayo Clin Proc 1986 61 442 447 2423813 (Pubitemid 16100857)
27. Impairment of starch absorption by a potent amylase inhibitor. WR Brugge MS Rosenfeld, Am J Gastroenterol 1987 82 718 722 2440298 (Pubitemid 17145096)
28. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. M Boivin AR Zinsmeister VL Go EP DiMagno, Mayo Clin Proc 1987 62 249 255 2436011 (Pubitemid 17052822)
29. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. M Boivin B Flourie RA Rizza VL Go EP DiMagno, Gastroenterology 1988 94 387 394 2446948 (Pubitemid 18054774)
30. Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying. NK Jain M Boivin AR Zinsmeister ML Brown JR Malagelada EP DiMagno, Gastroenterology 1989 96 377 387 2463204 (Pubitemid 19045268)
31. Evaluation of the Generally Recognized as Safe (GRAS) status of Phase 2 white bean (Phaseolus vulgaris) extract. R Nicolosi D Hughes D Bechtel, Bridgewater, NJ, Cantox Health Sciences International 2007 http://www. phase2info.com/pdf/science-dossier/phase2-gras-expert-report.pdf Ref Type: Online Source
32. The mighty bean. K Udani, European Baker 2005
33. Phase 2/Starch Lite. Y Das, Piscataway, NJ, ISSI Laboratories, Inc 2007 http://www.phase2info.com/pdf/Phase2-Study13.pdf ISSI no. P25036, 1-7. Ref Type: Online Source
34. Phase 2/Starch Lite in Chewing Gum. Y Das, Piscataway, NJ, ISSI Laboratories, Inc 2007 http://www.phase2info.com/pdf/Phase2-Study14.pdf ISSI no. P25036-B, 1-4. Ref Type: Online Source
35. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. L Celleno MV Tolaini A D'Amore NV Perricone HG Preuss, Int J Med Sci 2007 4 45 52 17299581 (Pubitemid 46168687)
36. Reduction in body weight with a starch blocking diet aid: StarchAway comparison with placebo. D Rothacker, Leiner Health Products 2003 http://www.phase2info.com/pdf/Phase2-Study6.pdf Ref Type: Online Source
37. Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. X Wu X Xu J Shen N Perricone H Preuss, Journal of Applied Research 2010 10 73 79
38. Blocking carbohydrate absorption and weight loss: a clinical trial using a proprietary fractionated white bean extract. J Udani BB Singh, Altern Ther Health Med 2007 13 32 37 17658120 (Pubitemid 351299280)
39. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. E Thom, J Int Med Res 2000 28 229 233 11092233
40. Thera-Slim for Weight Loss: A randomized double-blind placebo controlled study. S Erner D Meiss, 2003 http://www.phase2info.com/pdf/Phase2-Study8.pdf Ref Type: Online Source
41. The antiobesity effect and the safety of taking "Phaseolamin(TM) 1600 diet". T Koike Y Koizumi L Tang K Takahara Y Saitou, J New Rem & Clin (Japanese) 2005 54 1 16
42. Random multicenter evaluation to test the efficacy of Phaseolus vulgaris (Precarb) in obese and overweight individuals. L Osorio J Gamboa, Internal Report 2005 http://www.phase2info.com/pdf/Phase2-Study10.pdf Ref Type: Online Source
43. Effects of combination of functional food materials on body weight, body fat percentage, serum triglyceride and blood glucose. J Yamada T Yamamoto T Yamaguchi, 2007 http://www.phase2info.com/pdf/Phase2-Study15.pdf Ref Type: Online Source
44. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. J Udani M Hardy DC Madsen, Altern Med Rev 2004 9 63 69 15005645 (Pubitemid 38364882)
45. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. J Vinson H Al Kharrat D Shuta, The Open Nutraceuticals Journal 2009 2 88 91 10.2174/1876396000902010088
46. Lowering the glycemic index of white bread using a white bean extract. JK Udani BB Singh ML Barrett HG Preuss, Nutr J 2009 8 52 10.1186/1475-2891-8-52 19860922
47. A preliminary assessment of the acute and subchronic toxicity profile of phase2: an alpha-amylase inhibitor. KB Harikumar AM Jesil MC Sabu R Kuttan, Int J Toxicol 2005 24 95 102 10.1080/10915810590936364 16036768 (Pubitemid 40840095)
48. Subchronic oral toxicity of a standardized white kidney bean (Phaseolus vulgaris) extract in rats. D Chokshi, Food Chem Toxicol 2007 45 32 40 10.1016/j.fct.2006.06.021 17045383 (Pubitemid 44792314)
49. Biosimilar therapeutics-what do we need to consider? H Schellekens, NDT Plus 2009 2 27 i36 10.1093/ndtplus/sfn177 19461855
50. US Biosimilar Pathway Unlikely to be Useddagger: Developers Will Opt for a Traditional BLA Filing. C Wiatr, BioDrugs 2011 25 63 67 10.2165/11588410- 000000000-00000 21222498